Immunotherapy for Ovarian/Fallopian Tube Cancer Patients

Elvin CHALABIYEVa , Zafer ARIKa
aHacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Türkiye

Chalabiyev E, Arık Z. Immunotherapy for ovarian/fallopian tube cancer patients. In: Şendur MAN, ed. Current Immunotherapy Landscape for Solid Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.110-2.

ABSTRACT
Among women, one of the leading causes of cancer-related mortality is ovarian cancer. The main course of treatment is surgery; adjuvant and systemic treatments may include immunotherapy, chemotherapy, and targeted therapy. Prior to beginning systemic treatment, it is advised that molecular markers such as homologous recombination status, microsatellite instability (MSI), and mutations in BRCA1 and BRCA2 be checked. Immune checkpoint inhibitors can be used in patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) ovarian cancer. In ongoing studies, new subgroups of patients will be identified where immunotherapy will be effective.

Keywords: Ovarian/epithelial carcinoma; immunotherapy; BRCA

Referanslar

  1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287-99. [Crossref]  [PubMed]  [PMC]
  2. Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, et al. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022;151(9):1535-41. [Crossref]  [PubMed]
  3. Debuquoy C, Romeo C, Vanacker H, Ray-Coquard I. Rare ovarian tumors: an update on diagnosis and treatment. Int J Gynecol Cancer. 2020;30(6):879-87. [Crossref]  [PubMed]
  4. Gaona-Luviano P, Medina-Gaona LA, Magaña-Pérez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020;9(4):47. [Crossref]  [PubMed]
  5. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-96. [Crossref]  [PubMed]  [PMC]
  6. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-6. [Crossref]  [PubMed]
  7. Plagens-Rotman K, Chmaj-Wierzchowska K, Pięta B, Bojar I. Modifiable lifestyle factors and ovarian cancer incidence in women. Ann Agric Environ Med. 2018;25(1):36-40. [Crossref]  [PubMed]
  8. Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract. 2017;4:4. [Crossref]  [PubMed]  [PMC]
  9. Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev. 2019;73:1-9. [Crossref]  [PubMed]
  10. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, et al.; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320-9. [Crossref]  [PubMed]
  11. Aravantinos G, Fountzilas G, Kosmidis P, Dimopoulos MA, Stathopoulos GP, Pavlidis N, et al.; Hellenic Cooperative Oncology Group. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol. 2005;16(7):1116-22. [Crossref]  [PubMed]
  12. Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721-31. Erratum in: Lancet Oncol. 2021;22(12):e539. [Crossref]  [PubMed]
  13. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Sevelda P, et al. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Ann Oncol. 2019;30:v894-v5. [Crossref]
  14. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al.; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391-402. [Crossref]  [PubMed]
  15. Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci. 2016;17(12):2113. [Crossref]  [PubMed]  [PMC]
  16. Grunewald T, Ledermann JA. Targeted Therapies for Ovarian Cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:139-52. [Crossref]  [PubMed]
  17. Berton D, Banerjee SN, Curigliano G, Cresta S, Arkenau H-T, Abdeddaim C, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study. Wolters Kluwer Health; 2021. [Crossref]
  18. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-13. [Crossref]  [PubMed]  [PMC]
  19. Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, et al.; ATALANTE/ENGOT-ov29 Investigators. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023;41(30):4768-78. [Crossref]  [PubMed]  [PMC]
  20. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother. 2004;53(10):844-54. [Crossref]  [PubMed]  [PMC]
  21. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154-8.
  22. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651-68. [Crossref]  [PubMed]  [PMC]
  23. Hahn AW, Gill DM, Pal SK, Agarwal N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017;9(8):681-92. [Crossref]  [PubMed]
  24. André T, Berton D, Curigliano G, Sabatier R, Tinker AV, Oaknin A, et al. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023;6(11):e2341165. [Crossref]  [PubMed]  [PMC]
  25. Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Johnson EA, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. American Society of Clinical Oncology; 2015. [Crossref]
  26. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Matsumura N, et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. American Society of Clinical Oncology; 2014. [Crossref]
  27. Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, et al. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5(3):393-401. [Crossref]  [PubMed]  [PMC]
  28. Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080-7. [Crossref]  [PubMed]
  29. Harter P, Trillisch F, Okamoto A, et al. Durvalumab with paclitaxel/carboplatin and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Results from the randomized, placebo-controlled phase III DUO-O/ENGOT-ov46/AGO-OVAR 23/GOG-3025 trial. Abstract LBA5506. Presented June 3, 2023. 2023 ASCO Annual Meeting; 2023.